Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Regeneron Pharmaceuticals...

    NASDAQ: REGN · Real-Time Price · USD
    572.59
    12.59 (2.25%)
    At close: Sep 15, 2025, 3:59 PM
    573.50
    0.16%
    After-hours: Sep 15, 2025, 07:56 PM EDT
    2.25%
    Bid 572.6
    Market Cap 59.65B
    Revenue (ttm) 14.21B
    Net Income (ttm) 4.46B
    EPS (ttm) 39.7
    PE Ratio (ttm) 14.42
    Forward PE 13.81
    Analyst Buy
    Ask 575
    Volume 930,221
    Avg. Volume (20D) 989,582
    Open 558.54
    Previous Close 560.00
    Day's Range 558.54 - 573.69
    52-Week Range 476.49 - 1165.85
    Beta 0.35

    About REGN

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol REGN
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for REGN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Regeneron Pharmaceuticals Inc. is scheduled to release its earnings on Oct 30, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription
    1 week ago
    -2.61%
    Regeneron Pharmaceuticals shares are trading lower... Unlock content with Pro Subscription
    3 weeks ago
    +3.36%
    Regeneron Pharmaceuticals shares are trading higher after the company announced an FDA extension of target action dates to Q4 2025 for two EYLEA HD 8mg regulatory submissions.
    news image

    1 week ago · seekingalpha.com

    Regeneron Pharmaceuticals, Inc. (REGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

    Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 7:00 AM EDT Company Participants Christopher Fenimore - Executive VP of Finance...

    news image

    1 week ago · seekingalpha.com

    Regeneron Pharmaceuticals, Inc. (REGN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

    Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 9:30 AM EDT Company Participants Ryan Crowe - Senior Vice President of Investor Rela...

    news image

    1 week ago · seekingalpha.com

    Regeneron Pharmaceuticals, Inc. (REGN) Presents At Cantor Global Healthcare Conference 2025 (Transcript)

    Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Cantor Global Healthcare Conference 2025 September 3, 2025 1:35 PM EDT Company Participants Ryan Crowe - Senior Vice President of Investor Relations & St...

    news image

    1 week ago · 247wallst.com

    Michael Burry of Big Short Fame Loves These 3 Stocks

    I'm a massive fan of Dr. Michael Burry, the man played by Christian Bale in The Big Short, not only because he's made some incredible (albeit high-stakes) calls, even in the years that followed his bi...

    news image

    1 week ago · seekingalpha.com

    Regeneron: Drug Pricing Woes Notwithstanding, Due For A Major Comeback

    Regeneron Pharmaceuticals, Inc. shares have lost >50% of their value over the past 12 months. Regeneron remains a powerhouse pharma however, despite threats to its key drug Eylea from generics and lon...

    2 weeks ago · youtube.com

    Final Trades: ServiceNow, Regeneron, Cisco Systems and Truist Financial

    The Investment Committee give you their top stocks to watch for the second half.

    news image

    2 weeks ago · https://thefly.com

    Regeneron price target raised to $781 from $753 at Bernstein

    Bernstein raised the firm's price target on Regeneron to $781 from $753 and keeps an Outperform rating on the shares. The firm adds myasthenia gravis to its model following the positive Phase 3 readou...

    news image

    2 weeks ago · reuters.com

    Regeneron's rare immune disorder therapy meets main goal of late-stage trial

    Regeneron Pharmaceuticals said on Tuesday its experimental therapy for treating patients with a rare immune disorder has met the main goal of a late-stage study.

    news image

    3 weeks ago · fool.com

    2 Biotech Stocks That Could Soar 21% and 245% According to Wall Street's Top Analysts

    Viking Therapeutics (VKTX 1.32%) and Regeneron Pharmaceuticals (REGN -1.45%) have faced challenges this year that have sunk their stock prices. The former is down by 37% this year, while the latter ha...

    news image

    3 weeks ago · zacks.com

    FDA Extends Review Period of REGN's Submission for Eylea HD

    The FDA extends action dates for Regeneron's Eylea HD filings following inspection findings at Catalent Indiana. Nonetheless, Eylea HD remains available through vial administration.

    Add to Watchlist